
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp has reported significant growth in its HEPLISAV-B sales, achieving a 39% year-over-year increase in the fourth quarter of 2024 and a 26% increase for the full year, totaling $268.4 million. The company has successfully expanded its market share to approximately 44% by the end of 2024, with expectations to capture at least 60% of a projected hepatitis B vaccination market exceeding $900 million by 2030. Further, Dynavax anticipates double-digit annual sales growth for HEPLISAV-B through 2030, fueled by increased penetration into the eligible adult population and re-vaccination practices.
Bears say
Dynavax Technologies faces significant challenges that contribute to a negative outlook for its stock, primarily due to the inherent risks associated with its product candidates, which may fail to meet efficacy or safety standards necessary for approval and commercialization. Additionally, the company struggles with the potential inability to effectively commercialize its products due to market dynamics, strong competition, and potential internal factors, which could impede its growth. Furthermore, notwithstanding a modest revenue report for Q4 2024, Dynavax has a history of financial losses and lacks a proven track record of profitability, heightening the uncertainty around its future performance.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares